<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Stevens-Johnson syndrome MeG-CLS-067</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h1 id="stevens-johnson-syndrome">Stevens-Johnson Syndrome</h1>
<h2 id="introduction">Introduction</h2>
<p>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous adverse reactions, most commonly triggered by medications, characterized by fever and extensive necrosis and detachment of the epidermis. SJS and TEN are considered a disease continuum and are distinguished chiefly by severity, based upon the percentage of body surface involved with skin detachment.</p>
<p>SJS is the less severe condition, in which skin detachment is &lt;10% of the body surface. Mucous membranes are affected in over 90 percent of patients, usually at two or more distinct sites (ocular, oral, and genital).</p>
<p>TEN involves detachment of &gt;30% of the body surface area. Mucous membranes are also involved in over 90% of cases.</p>
<p>SJS/TEN overlap describes patients with skin detachment of 10 to 30% of body surface area. Mucous membranes are also involved in over 90% of cases.</p>
<p>Here, &quot;SJS/TEN&quot; is used to refer collectively to SJS, TEN, and SJS/TEN overlap.</p>
<h2 id="target-user">Target User</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nurses</p>
</div></li>
</ul>
<h2 id="target-area-of-use">Target area of use </h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Ward</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Outpatient department</p>
</div></li>
</ul>
<h2 id="key-areas-of-focusnew-additionschanges">Key areas of focus/new additions/changes</h2>
<p>These guidelines addresses the management of Stevens Johnson.</p>
<h2 id="limitations">Limitations</h2>
<p>Lack of an intensive care unit to nurse patient with extensive lesions.</p>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<p>Typical prodromal symptoms of SJS are as follows:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Cough productive of a thick, purulent sputum</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Headache</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Malaise</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Arthralgia</p>
</div></li>
</ul>
<p>Patients may complain of a burning rash that begins symmetrically on the face and the upper part of the torso. This may be accompanied by ocular symptoms.</p>
<p>In addition to the skin, lesions in SJS may involve the following parts of the body:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Oral mucosa</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Oesophagus</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Pharynx</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Larynx</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Anus</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Trachea</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Vagina</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Urethra</p>
</div></li>
</ul>
<p>Ocular symptoms include the following: red eye, tearing, dry eye, pain, blepharospasm, itching, grittiness, heavy eyelid, foreign body sensation, decreased vision, burning sensation, photophobia, diplopia</p>
<h2 id="examination-findings">Examination findings</h2>
<p>The rash can begin as macules that develop into papules, vesicles, bullae, urticarial plaques, or confluent erythema. The centre of these lesions may be vesicular, purpuric, or necrotic.</p>
<p>Lesions may become bullous and later rupture, leaving denuded skin. The skin becomes susceptible to secondary infection.</p>
<p>Urticarial lesions typically are not pruritic. Infection may be responsible for the scarring associated with morbidity.</p>
<p>Although lesions may occur anywhere, the palms, soles dorsum of the hands, and extensor surfaces are most commonly affected.</p>
<p>The rash may be confined to any one area of the body, most often the trunk. Mucosal involvement may include erythema, oedema, sloughing, blistering, ulceration, and necrosis.</p>
<p>The following signs may also be noted on examination:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Fever</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Tachycardia</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hypotension</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Altered level of consciousness, epistaxis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Conjunctivitis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Corneal ulceration</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Erosive vulvovaginitis or balanitis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Seizures</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Coma</p>
</div></li>
</ul>
<h2 id="differential-diagnoses">Differential Diagnoses</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Trauma</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Irradiation</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Porphyria cutanea tarda</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Staphylococcal scalded skin syndrome</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Sebaceous cell carcinoma</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Adenoviral conjunctivitis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Intraepithelial epithelioma</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Acute generalized exanthematic pustulosis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Chemical burns</p>
</div></li>
</ul>
<h2 id="investigations">Investigations</h2>
<p>There are no specific laboratory studies (other than biopsy) that can definitively establish the diagnosis of SJS but the following investigations can be done:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>FBC, severely elevated WBC count indicates the possibility of a superimposed bacterial infection.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>U&amp;E, LFT may be needed to help manage related problems</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Skin and blood cultures have been advocated because the incidence of serious bacterial bloodstream infections and sepsis contribute to morbidity and mortality.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>CXR may indicate the existence of a pneumonitis when clinically suspected. Otherwise, routine plain films are not indicated.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Skin biopsy specimens demonstrate that the bullae are subepidermal. Epidermal cell necrosis may be noted. Perivascular areas are infiltrated with lymphocytes.</p>
</div></li>
</ul>
<h2 id="management">Management</h2>
<p>The main principles of supportive care are the same as for major burns and include wound care, fluid and electrolyte management, nutritional support, temperature management, pain control, and monitoring or treatment of superinfections</p>
<h3 id="initiate-a-primary-management-plan">Initiate a primary management plan:</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Establish peripheral venous access: Site venous lines through non-lesional skin, whenever possible, and change peripheral venous cannulas every 48 hours.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Establish adequate intravenous fluid replacement initially. Fluid replacement can be guided by urine output and other endpoint measurements. Individualized fluid management should be adjusted on a daily basis, but replacement volumes are approximately one-third lower than those needed for burn victims.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>With improvement of SJS/TEN mouth involvement, oral administration of fluids should be progressively increased.</p>
</div></li>
</ul>
<div data-custom-style="List Paragraph">
<p>If patient cannot maintain adequate nutrition orally, insert a nasogastric tube and institute nasogastric feeding.</p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Insert a urinary catheter if urogenital involvement is causing significant dysuria/retention.</p>
</div></li>
</ul>
<h3 id="prognostic-scoring">Prognostic scoring </h3>
<p>The prognosis of individual patients can be rapidly evaluated on admission by applying a prognostic scoring system called <strong>SCORTEN</strong>. SCORTEN is based upon seven independent and easily measured clinical and laboratory variables <span class="underline"> </span> and has been validated for use on days one and three of hospitalization for SJS/TEN.</p>
<table>
<thead>
<tr class="header">
<th><strong>Prognostic factors</strong></th>
<th><strong>Score</strong></th>
<th></th>
<th><strong>SCORTEN</strong></th>
<th><strong>Mortality(%)</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Age &gt; 40 years</td>
<td>1</td>
<td></td>
<td>0-1</td>
<td>3</td>
</tr>
<tr class="even">
<td>Tachycardia &gt;120 bpm</td>
<td>1</td>
<td></td>
<td>2</td>
<td>12</td>
</tr>
<tr class="odd">
<td>Neoplasia</td>
<td>1</td>
<td></td>
<td>3</td>
<td>35</td>
</tr>
<tr class="even">
<td>Initial detachment &gt; 10%</td>
<td>1</td>
<td></td>
<td>4</td>
<td>58</td>
</tr>
<tr class="odd">
<td>Serum urea &gt; 10 mmol/L</td>
<td>1</td>
<td></td>
<td>≥5</td>
<td>90</td>
</tr>
<tr class="even">
<td>Serum bicarbonate &lt; 20 mmol/L</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td>Blood glucose &gt; 14 mmol/L</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>The decision to refer the patient to an intensive care or burn unit should be made on a case-by-case basis, based upon the extent of skin involvement and the presence of comorbidities. Patients with a limited skin involvement, a SCORTEN score <span class="underline"> </span> of 0 or 1, and disease that is not rapidly progressing may be treated in nonspecialized wards. Patients with more severe disease (skin detachment &gt;30% of the body surface area) <span data-custom-style="Strong">or</span> a SCORTEN score ≥2 should be transferred to intensive care units, burn units, or specialized dermatology units, if available.</p>
<h3 id="skin-care">Skin Care </h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Employ strict barrier nursing to reduce nosocomial infections</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Take swabs for bacterial and candidal culture from three areas of lesional skin, particularly sloughy or crusted areas, on alternate days throughout the acute phase.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Administer systemic antibiotics only if there are clinical signs of infection</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Regularly cleanse wounds and intact skin by irrigating gently using warmed sterile water, saline or an antimicrobial such as chlorhexidine (1/5000)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Apply a greasy emollient, such as emulsifying ointment, 50% white soft paraffin with 50% liquid paraffin, over the whole epidermis, including denuded areas</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Apply a topical antimicrobial agent to sloughy areas only (choice should be guided by local microbiological advice·</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>The detached, lesional epidermis may be left <em>in situ</em> to act as a biological dressing. Blisters should be decompressed by piercing and expression or aspiration of tissue fluid.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Apply non-adherent dressings to denuded dermis</p>
</div></li>
</ul>
<h3 id="analgesia">Analgesia</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Use a patient appropriate validated pain tool to assess pain in all conscious patients at least once a day.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Patients should receive adequate analgesia to ensure comfort at rest, with the addition of supplementary opiates, as required.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Additional analgesia may be needed to address increased pain associated with patient handling, re-positioning and dressing changes</p>
</div></li>
</ul>
<h3 id="supportive-therapeutic-measures">Supportive therapeutic measures</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Immobile patients should receive low molecular weight heparin</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Patients in whom enteral nutrition cannot be established should receive a proton pump inhibitor to reduce the risk of stress-related gastro-intestinal ulceration</p>
</div></li>
</ul>
<h3 id="ocular-care">Ocular Care</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Apply an ocular lubricant (e.g. non-preserved hyaluronate or carmellose eye drops) every two hours through the acute illness</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ocular hygiene must be carried out each day</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Application of topical corticosteroid drops (e.g. non-preserved dexamethasone 0.1% twice a day) may reduce ocular surface damage</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Administer topical antibiotic as prophylaxis (e.g. ciprofloxacin drops four times a day) in the presence of corneal ulceration</p>
</div></li>
</ul>
<ul>
<li><div data-custom-style="List Paragraph">
<p>In the unconscious patient, prevention of corneal exposure is essential.</p>
</div></li>
</ul>
<h3 id="mouth-care">Mouth care</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Daily oral review is necessary during the acute illness</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Apply white soft paraffin ointment to the lips every two hours through the acute illness</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Clean the mouth daily with warm saline mouthwashes or an oral sponge</p>
</div></li>
</ul>
<h3 id="urogenital-caret">Urogenital Caret</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Daily urogenital review is necessary during the acute illness</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Apply white soft paraffin ointment to the urogenital skin and mucosae every four hours throughout the acute illness</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Use a potent topical corticosteroid ointment once a day to the involved, but non-eroded surfaces.</p>
</div></li>
</ul>
<h3 id="nutritional-care-of-airway">Nutritional care of airway</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Provide continuous enteral nutrition throughout the acute phase</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Deliver up to 20 to 25 kcal/kg/day during the early, catabolic phase and 25 to 30 kcal/kg/day during the anabolic, recovery phase.</p>
</div></li>
</ul>
<h3 id="discharge-and-follow-up">Discharge and follow up</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Give the patient written information about drug(s) to avoid</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Drug allergy should be documented in the patient’s notes; all doctors involved in the patient’s care should be informed</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Organize an out-patient clinic appointment, and if required an ophthalmology out-patient appointment, within a few weeks of discharge</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Refer for review to unit with appropriate sub-speciality interest</p>
</div></li>
</ul>
<h2 id="key-issues-for-nursing-care">Key Issues for Nursing care</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Sterile handling and/or reverse-isolation nursing techniques are essential to decrease the risk of nosocomial infection</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Daily ocular and mouth hygiene</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Effective and timely skin care</p>
</div></li>
</ul>
<h2 id="references">References</h2>
<ol type="1">
<li><blockquote>
<p><a href="https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae/abstract/1">Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129:92.</a></p>
</blockquote></li>
<li><blockquote>
<p><a href="https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae/abstract/2">Creamer D, Walsh SA, Dziewulski P, et al. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol 2016; 174:1194.</a></p>
</blockquote></li>
<li><blockquote>
<p><a href="https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae/abstract/3">Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010; 5:39.</a></p>
</blockquote></li>
<li><blockquote>
<p><a href="https://www.uptodate.com/contents/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae/abstract/4">Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115:149.</a></p>
</blockquote></li>
<li><blockquote>
<p><strong>UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis 2016</strong> Creamer D, Walsh SA , Dziewulski P, Exton LS, Lee HY, Dart JKG, Setterfield J, Bunker CB, Ardern-Jones MR, Watson KMT,Wong GAE, Philippidou M, Vercueil A, Martin RV, Williams G, Shah M, Brown D, Williams P, Mohd Mustapa MF, Smith CH.</p>
</blockquote></li>
<li><blockquote>
<p><em>Br J Dermatol</em> <strong>2016</strong>; 174: 1194-1227 &amp; <em>J Plast Reconstr Aesthet Surg</em> <strong>2016</strong>; 69: e119e153</p>
</blockquote></li>
</ol>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Name: Amie Secka</th>
<th>Date: 30 November 2018</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Orighomisan Agboghoroma</td>
<td>Date: 06 December 2018</td>
</tr>
<tr class="even">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="odd">
<td>1.0</td>
<td>New document</td>
<td>31 January 2021</td>
</tr>
<tr class="even">
<td>1.1</td>
<td>Executive summary added</td>
<td>31 January 2021</td>
</tr>
<tr class="odd">
<td>Review Comments (<em>if applicable)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
